NCT03911973 2024-06-07
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting
Clinical Trials
5 trialsNCT02626507 2022-02-09
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
Hoffman Oncology
Phase 1 Unknown
NCT03698383 2021-02-18
Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer
Korean Cancer Study Group
Phase 2 Unknown
NCT03243331 2021-01-07
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
Indiana University
Phase 1 Completed
NCT03400254 2020-04-28
GLACIER
Abramson Cancer Center at Penn Medicine
Phase 1/2 Withdrawn